Abstract
Lebrikizumab (LEB) was studied for treating immune mediated disorders, including asthma and atopic dermatitis. LAVOLTA I (NCT01867125) and II (NCT01868061) (LI&LII) were duplicate randomized, placebo-controlled Phase 3 LEB trials in uncontrolled asthma that enrolled subjects irrespective of asthma exacerbation history, baseline blood eosinophilia, or FeNO. LI&II failed to show consistently significant results in asthma exacerbation rate reduction. Here, effects of LEB on inflammatory biomarkers were assessed in patients with asthma.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
